公开(公告)号：NZ719163A

公开(公告)日：2021-01-29

申请号：NZ71916314

申请日：2014-10-17

Applicant: VERTEX PHARMA

Inventor： KADIYALA IRINA ,  MUDUNURI PRAVEEN ,  WALDO MICHAEL ,  NTI-ADDAE KWAME ,  O’NEIL SIMON ,  ZHANG YUEGANG ,  SONG BIN ,  VAN ALSTEN JOHN GREGG ,  STROHMEIER MARK ,  STAVROPOULOS KATHY ,  NAVAMAL METTACHIT

IPC: C07D401/14 ,  A61K31/506 ,  A61P35/00

Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. The co-crystals of (S)-N-methyl-8-(1-((2’-methyl-[4,5’-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide with adipic acid are DNA-dependent protein kinase (DNA-PK) inhibitors which may be useful for the treatment of cancer.

公开(公告)号：NZ719729A

公开(公告)日：2022-04-29

申请号：NZ71972914

申请日：2014-11-12

Applicant: VERTEX PHARMA

Inventor： ASMAL MOHAMMED ,  LEDEBOER MARK ,  MEDEK ALES ,  MUDUNURI PRAVEEN ,  WALDO MICHAEL ,  O’NEIL SIMON ,  VAN ALSTEN JOHN GREGG ,  NTI-ADDAE KWAME ,  MACIKENAS DAINIUS ,  SHI YI ,  JURKAUSKAS VALDAS ,  JONES STEVEN ,  BYRN RANDAL ,  ROBERTSON SARAH ,  TSAI WANJUNG

IPC: C07D403/04 ,  A61K31/506 ,  A61P31/16 ,  C07D471/04

Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1)·1/2Η20, Form F of HCl salt of Compound (1)·3Η20, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.